The current agreement between the Commonwealth and the research-based pharmaceutical industry promised faster access to new medicines through HTA reforms. Four years on, that reform is still unfinished. In the first of two articles, Jody Fassina of Insight Strategy asks what was promised, what was delivered and who pays while patients wait.
Access delayed - the stakes are high for the industry's next agreements
October 27, 2026 Latest NewsBioPharmaCommentNews of the Day
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 6 November
November 6, 2026 - - Podcast -
Omico names laboratory partners to expand genomic profiling for Australians with cancer
November 6, 2026 - - Latest News -
Marie Guillet joins the European Australian Business Council board
November 6, 2026 - - Latest News -
The next agreements must end the culture of enforced silence
November 6, 2026 - - Latest News -
The lessons we can take from 'Robodebt' and the Reserve Bank reforms
November 6, 2026 - - Latest News -
Vaccines dominate public health spending but prevention investment slips
November 5, 2026 - - Latest News -
Increased accountability can be the only response to expanding authority
November 5, 2026 - - Latest News
